. 2001 Jul 6;2(4):155–159. doi: 10.1186/cvm-2-4-155

Table 2.

Effect of ramipril on echocardiographic measurements of left ventricular mass and function in a substudy of HOPE

Echocardiographic variable	Placebo	Ramipril 2.5 mg/day	Ramipril 10 mg/day
Δ LVMI (g/m²)	3.98 ± 25.23	4.15 ± 22.77	-2.02 ± 27.12^*
Δ LVEF (%)	-2.02 ± 1.54	-1.54 ± 8.94	-0.17 ± 8.62^†
Δ LVEDV (ml)	4.16 ± 30.89	-0.43 ± 33.3	-5.90 ± 35.17^††
Δ LVESV (ml)	5.31 ± 20.49	2.90 ± 17.68	-1.90 ± 18.71^††
New wall motion abnormalities	31	30	23

^*P < 0.05. ^†P = 0.06. ^††P < 0.01. Δ refers to study-end minus baseline measurement. HOPE =Heart Outcomes Prevention Evaluation study; LVMI = left ventricular mass index; LVEF = left ventricular ejection fraction; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume.